First Phase 3 Clinical Trials Targeting the Tauopathy of Alzheimer's Disease

Claude Wischik, Professor of Old Age Psychiatry, University of Aberdeen; Executive Chairman, TauRX Therapeutics, Ltd.

Video Overview

Claude Wischik is Professor of Old Age Psychiatry at the University of Aberdeen and Executive Chairman of TauRx Therapeutics. He studied medicine in Australia, then PhD and post-doctoral research at the MRC Laboratory of Cambridge, UK. He also completed psychiatric training in Cambridge.

During his PhD he discovered that the neurofibrillary tangle is composed of the microtubule associated protein Tau. He also discovered that they could be dissolved by diaminophenothiazines. He established a team which developed in vitro and in vivo systems to establish plausibility of developing Tau Aggregation Inhibitor (TAI) therapy for AD.

He cofounded TauRx Therapeutics to develop diagnostics and therapeutics for AD based on the TAI approach. In the first ever TAI phase 2 trial, TauRx demonstrated the feasibility of arresting disease progression over 12 months. TauRx is currently conducting a global phase 3 trial of its lead compound in approximately 1,500 subjects in 22 countries.